Literature DB >> 16978291

The role of the lymphatic system and its specific growth factor, vascular endothelial growth factor C, for lymphogenic metastasis in prostate cancer.

Lutz Trojan1, Florian Rensch, Martin Voss, Rainer Grobholz, Christel Weiss, David G Jackson, Peter Alken, Maurice S Michel.   

Abstract

OBJECTIVE: To compare prostate carcinoma, with and with no lymph node metastasis, to benign prostatic hyperplasia (BPH) tissue for lymphatic vessel density (LVD) and the expression of the lymph-endothelial specific growth factor, vascular endothelial growth factor C (VEGF-C), to determine their role in lymphogenic metastasis. PATIENTS,
MATERIALS AND METHODS: Lymphatic vessels were stained using lymphatic vessel endothelial hyaluronan receptor 1 and assessed in standard areas. The expression of VEGF-C was assessed by the number of positive epithelial cells. The data were compared with the clinical staging.
RESULTS: The lowest LVD was found in tumorous areas as opposed to periphery and nontumorous tissue (P = 0.007; P < 0.001). The highest LVD was in BPH tissue (P < 0.001). There was no correlation with clinical staging. There was more VEGF-C staining in pN1 than in pN0 and in BPH specimens (P = 0.002).
CONCLUSION: LVD is not a prognostic variable for the process of lymphogenic metastasis in prostate cancer. VEGF-C is up-regulated in prostate cancer and its correlation with lymph node status suggests a role for the development of lymph node metastasis, e.g. via an increased permeability of lymphatic vessels.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16978291     DOI: 10.1111/j.1464-410X.2006.06403.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  8 in total

Review 1.  Mechanism of lymph node metastasis in prostate cancer.

Authors:  Kaustubh Datta; Michael Muders; Heyu Zhang; Donald J Tindall
Journal:  Future Oncol       Date:  2010-05       Impact factor: 3.404

2.  Systemic blockade of the hyaluronan receptor for endocytosis prevents lymph node metastasis of prostate cancer.

Authors:  Melanie A Simpson; Janet A Weigel; Paul H Weigel
Journal:  Int J Cancer       Date:  2012-02-28       Impact factor: 7.396

3.  Expression of vascular endothelial growth factor C in human pterygium.

Authors:  Junichi Fukuhara; Satoru Kase; Tsutomu Ohashi; Ryo Ando; Zhenyu Dong; Kousuke Noda; Takeshi Ohguchi; Atsuhiro Kanda; Susumu Ishida
Journal:  Histochem Cell Biol       Date:  2012-08-23       Impact factor: 4.304

4.  Modulating metastasis by a lymphangiogenic switch in prostate cancer.

Authors:  Ebba Brakenhielm; Jeremy B Burton; Mai Johnson; Nelson Chavarria; Kouki Morizono; Irvin Chen; Kari Alitalo; Lily Wu
Journal:  Int J Cancer       Date:  2007-11-15       Impact factor: 7.396

5.  The clinical significance of lymphangiogenesis in renal cell carcinoma.

Authors:  Paweł Dębiński; Janusz Dembowski; Paweł Kowal; Tomasz Szydełko; Anna Kołodziej; Bartosz Małkiewicz; Krzysztof Tupikowski; Romuald Zdrojowy
Journal:  Med Sci Monit       Date:  2013-07-24

6.  miR-101 suppresses vascular endothelial growth factor C that inhibits migration and invasion and enhances cisplatin chemosensitivity of bladder cancer cells.

Authors:  Ye Lei; Bin Li; Shiyu Tong; Lin Qi; Xiheng Hu; Yunbo Cui; Zengbo Li; Wei He; Xiongbing Zu; Zhi Wang; Minfeng Chen
Journal:  PLoS One       Date:  2015-02-06       Impact factor: 3.240

7.  The expression of vascular endothelial growth factor-C correlates with lymphatic microvessel density and lymph node metastasis in prostate carcinoma: An immunohistochemical study.

Authors:  Gyftopoulos Kostis; Lilis Ioannis; Kourea Helen; Papadaki Helen
Journal:  Urol Ann       Date:  2014-07

8.  Immunohistochemical characterization of lymphangiogenesis-related biomarkers in primary and recurrent gliomas: A STROBE compliant article.

Authors:  Jun Jiang; Shun Wang; Yuan Chen; Chengwei Wang; Chuncheng Qu; Yuguang Liu
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.889

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.